Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Anavex Life Sciences (AVXL – Research Report). The associated price target remains the same with $42.00.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Anavex Life Sciences’ promising developments. The completion of enrollment in the Phase 2 clinical trial for ANAVEX3-71, aimed at treating schizophrenia, is a significant milestone. This trial’s results, expected in the second half of 2025, could potentially lead to late-stage clinical development if positive. The novel mechanism of ANAVEX3-71, which targets multiple symptom domains without the side effects of current antipsychotics, positions it as a potentially superior treatment option in a market valued at over $10 billion annually in the U.S.
Additionally, Anavex’s lead candidate, blarcamesine, is under review by European regulators, with a decision anticipated by the end of the year. The European market presents a lucrative opportunity, given the growing number of Alzheimer’s patients. Approval in Europe could pave the way for further regulatory submissions in other regions, such as the UK, Canada, and Australia, enhancing the company’s global market potential. These strategic developments underpin Selvaraju’s confidence in Anavex’s growth prospects, justifying the Buy rating and a 12-month price target of $42.